{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-000238","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2024-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.574635+00:00","generated_at":"2026-06-07T05:05:41.337722+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"SCYNEXIS amends GSK license after BREXAFEMME recall; milestone payments cut","bullets":["Binding MOU amends March 2023 license after beta-lactam contamination risk triggered BREXAFEMME recall and clinical hold.","Regulatory milestone cap reduced to $49M (from $70M); commercial milestone cap to $57.5M (from $115M).","Sales milestone caps lowered to $179.5M/$169.75M/$145.5M (from $242.5M), depending on relaunch date.","Up to $72.35M in development milestones, including $30M for MARIO study resumption after clinical hold lifted.","GSK already paid $90M upfront and $25M development milestone; royalty rates unchanged (mid-single to mid-teen)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-000238","json":"https://secwatch.observer/filing/0000950170-24-000238.json","markdown":"https://secwatch.observer/filing/0000950170-24-000238.md","text":"https://secwatch.observer/filing/0000950170-24-000238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000095017024000238/0000950170-24-000238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000095017024000238/scyx-20231226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:05:41.337722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33c252ca077450b260bff99762f2b944004b4f5a","claim":"SCYNEXIS INC amended Binding Memorandum of Understanding for Amendment to License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited (effective 2023-12-26).","evidence_excerpt":"On December 26, 2023, SCYNEXIS, Inc. (“SCYNEXIS”) and GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”) entered into a binding memorandum of understanding (“Binding MOU”) for amendment to the exclusive license agreement between SCYNEXIS and GSK, dated March 30, 2023","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017024000238/0000950170-24-000238-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"GlaxoSmithKline Intellectual Property (No. 3) Limited"},{"label":"Effective","value":"2023-12-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}